Research teams from Cedars-Sinai Heart Institute and the Minneapolis Heart Institute with funding from CIRM [California Institute for Regenerative Medicine] are moving to Phase 2 Clinical Trials for a treatment that utilizes cardiac stem cells to repair severe heart damage. The treatment development was led by Eduardo Marbán, a director at the Cedars-Sinai Heart Institute and founder of Capricor. This groundbreaking treatment involves the injection of stem cells into the coronary artery, which then migrate to the heart and promote the regrowth of healthy heart muscle.
Topics: Heart Valve, Phase III, Heart, stemsaveblog, Acute Myocardial Infarction, Heart Failure, clinical trials, Debilitating Diseases, Phase II, Stemcells, Heart Attack, autologousstemcells, heart disease
Scientists from the Mediterranean Institute of Haematology have developed a treatment that utilizes stem cells from umbilical cord blood to cure children of a life-threatening blood disorder called Thalassemia Major. The procedure involves the transplantation of stem cells from cord blood into the Thalassemia patient. Recent applications [in India] of this breakthrough procedure have resulted in several children being cured of the disease.
The Ninth Annual Stem Cell Summit will take place on February 18th in New York City. The summit will feature presentations from the stem cell industry’s premier researchers, executives, and investors to address recent advances and this year’s expectations of the Stem Cell / Regenerative Medical industry.
Researchers at the Virginia Commonwealth University’s Masey Cancer Center have developed an innovative approach to the treatment of multiple myeloma. The Phase II Clinical trial involves a process to ‘mark’ cancerous cells and also boost the body’s immune system – by removing the patient’s stem cells, manipulating them in-vitro [outside the body] and then reintroducing the stem cells back into the patient - to destroy the cancerous cells. Researchers believe the reprogrammed stem cells will also prevent any future recurrence of multiple myeloma.